Compare PRME & NRIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRME | NRIM |
|---|---|---|
| Founded | 2019 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 526.0M | 531.6M |
| IPO Year | 2022 | 2002 |
| Metric | PRME | NRIM |
|---|---|---|
| Price | $4.23 | $23.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 3 |
| Target Price | $7.03 | ★ $28.33 |
| AVG Volume (30 Days) | ★ 5.5M | 123.5K |
| Earning Date | 11-12-2026 | 10-15-2026 |
| Dividend Yield | N/A | ★ 2.84% |
| EPS Growth | ★ 18.18 | N/A |
| EPS | N/A | ★ 1.92 |
| Revenue | $4,632,000.00 | ★ $255,581,000.00 |
| Revenue This Year | $18.58 | $1.76 |
| Revenue Next Year | $23.34 | $25.33 |
| P/E Ratio | ★ N/A | $12.47 |
| Revenue Growth | ★ 55.28 | 30.43 |
| 52 Week Low | $2.67 | $21.94 |
| 52 Week High | $5.91 | $30.82 |
| Indicator | PRME | NRIM |
|---|---|---|
| Relative Strength Index (RSI) | 51.32 | 41.37 |
| Support Level | $2.94 | $23.42 |
| Resistance Level | $4.80 | $25.33 |
| Average True Range (ATR) | 0.53 | 0.62 |
| MACD | -0.08 | 0.02 |
| Stochastic Oscillator | 22.25 | 6.65 |
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
Northrim BanCorp Inc is a bank holding company operating through three reportable segments: Community Banking, Home Mortgage Lending, and Specialty Finance. The Community Banking segment, which generates the majority of revenue, provides loan and deposit products to business and consumer customers in its market areas. The Home Mortgage Lending segment focuses on the origination and sale of mortgage loans for one-to-four family residential properties, mortgage loan servicing for certain loans sold, and investment in selected residential mortgage loans. The Specialty Finance segment provides factoring, asset-based lending, and alternative working capital solutions to small and medium-sized enterprises and includes SCF and Northrim Funding Services.